Brian Dymock currently leads the group on medicinal and computational chemistry and biology at QEDDI, UniQuest, working on small molecule preclinical drug discovery. Dr. Dymock has 24 years’ experience in drug discovery research and development in pharmaceutical companies, biotech and academia. He was an associate professor in Medicinal Chemistry at the National University of Singapore for 5 years, where he published 40 papers in medicinal chemistry. Prior to that, Dr. Dymock was head of chemistry for S*BIO Pte Ltd in Singapore, where his team was responsible for the discovery of chemotherapeutics including Pacritinib (NDA filed) and Pracinostat (Phase 3). He also led the chemistry team at Vernalis discovering the experimental anti-cancer candidate Luminespib in collaboration with the Institute of Cancer Research. At UniQuest, Dr. Dymock has been responsible for work on anti-inflammatory drugs for the treatment of PD since the project’s inception